Allogene ‘CAR T-wheels’ into cancer immunotherapy on the tail of a Kite – BioWorld Online
BioWorld Online |
Allogene 'CAR T-wheels' into cancer immunotherapy on the tail of a Kite
BioWorld Online The formation of Allogene Therapeutics, which took off with a $300 million series A financing and a portfolio of assets from Pfizer Inc. related to allogeneic chimeric antigen receptor T cell (CAR T) therapy, began with a conversation at a dinner on … |
